1,3-dibutyl-8-methyl-3,7-dihydropurine-2,6-dione | 263552-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-dibutyl-8-methyl-3,7-dihydropurine-2,6-dione
• 英文别名: 1,3-dibutyl-8-methyl-3,7-dihydro-purine-2,6-dione；1,3-Dibutyl-8-methyl-3,7-dihydro-purin-2,6-dion；1,3-dibutyl-8-methyl-7H-purine-2,6-dione
• CAS: 263552-78-9
• 化学式: C₁₄H₂₂N₄O₂
• 分子量: 278.354
• InChiKey: FMKAFIKABTUVPN-UHFFFAOYSA-N

物化性质

• 熔点：
  158-159 °C
• 沸点：
  492.4±37.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-dibutyl-8-methyl-3,7-dihydropurine-2,6-dione 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 30.0h， 以69%的产率得到1,3-dibutyl-8-methyl-6-thioxanthine
  参考文献：
  名称：

  [EN] THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS
  [FR] DERIVES DE THIOXANTHINE UTILISES COMME INHIBITEURS DE LA MYELOPEROXYDASE

  摘要：

  本文披露了化合物的使用，其化学式为(Ia)或(Ib)，其中R1、R2、R3、R4、X和Y如规范中所定义，以及其药用可接受的盐，在制备药物时用于治疗或预防通过抑制酶髓过氧化物酶（MPO）对疾病或情况有益的药物。本文披露了化学式(Ia)或(Ib)的某些新型化合物及其药用可接受的盐，以及其制备过程。化学式(Ia)和(Ib)的化合物是MPO抑制剂，因此在神经炎症性疾病的治疗或预防中特别有用。

  公开号：

  WO2003089430A1
• 作为产物：
  描述：

  6-氨基-1,3-二丁基-5-亚硝基-2,4(1H,3H)-嘧啶二酮 在 ammonium sulfide 、 水 作用下， 反应 0.0h， 生成 1,3-dibutyl-8-methyl-3,7-dihydropurine-2,6-dione
  参考文献：
  名称：

  Some Alkyl Homologs of Theophylline

  摘要：

  DOI：

  10.1021/ja01097a032

文献信息

• Method of treating bone loss by stimulation of calcitonin
  申请人：American Home Products Corporation

  公开号：US06221874B1

  公开（公告）日：2001-04-24

  Compounds of the formula R1 and R2 are independently alkyl of 1 to 6 carbon atoms, allyl, or substituted allyl of 3 to 6 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, or cycloalkyl of 3 to 10 carbon atoms; and R4 is phenyl or naphthyl substituted with alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or NR5R6; substituted or unsubstituted phenylalkyl wherein the alkyl group contains 1 to 6 carbon atoms; substituted or unsubstituted 5 to 10 membered heteroaryl having 1 to 3 heteroatoms selected from N, S and O; substituted or unsubstituted cycloalkyl of 3 to 10 carbon atoms; or substituted or unsubstituted cycloalkylalkyl of 4 to 10 carbon atoms; provided that phenyl or naphthyl is substituted with NR5R6 when R1 and R2 is alkyl, are useful in the treatment of various disorders associated bone loss by increased transcription and elevation of plasma calcitonin levels. Such disorders include, but are not limited to: Paget's Disease, post menopausal osteoporosis, senile osteoporosis, and glucocorticoid-induced osteoporosis.

  化合物的公式为R1和R2，分别独立地是1到6个碳原子的烷基，烯丙基或3到6个碳原子的取代烯丙基；R3是氢，1到6个碳原子的烷基或3到10个碳原子的环烷基；R4是苯或萘基，取代有1到6个碳原子的烷基，1到6个碳原子的烷氧基或NR5R6；取代或未取代的苯基烷基，其中烷基含有1到6个碳原子；取代或未取代的5到10元杂环芳基，其中有1到3个N、S和O杂原子；取代或未取代的3到10个碳原子的环烷基；或取代或未取代的4到10个碳原子的环烷基烷基；前提是当R1和R2是烷基时，苯或萘基取代有NR5R6。这些化合物在治疗与骨丢失有关的各种疾病中是有用的，通过增加转录和升高血浆降钙素水平。这些疾病包括但不限于：帕吉特病，绝经后骨质疏松症，老年性骨质疏松症和糖皮质激素诱导性骨质疏松症。
• Some Alkyl Homologs of Theophylline
  作者：John H. Speer、Albert L Raymond

  DOI：10.1021/ja01097a032

  日期：1953.1
• A 3 ADENOSINE RECEPTOR AGONISTS
  申请人：THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services

  公开号：EP0708781A1

  公开（公告）日：1996-05-01
• US6221874B1
  申请人：——

  公开号：US6221874B1

  公开（公告）日：2001-04-24
• Novel and Selective Calcitonin-Inducing Agents
  作者：Adam M. Gilbert、Stephen Caltabiano、Denise Roberts、Sam F. W. Sum、Gerardo D. Francisco、Kitae Lim、Magda Asselin、John W. Ellingboe、Yogendra Kharode、Anna Cannistraci、Rita Francis、Mark TrailSmith、David Gralnick

  DOI：10.1021/jm990558l

  日期：2000.3.1

  A series of xanthine sulfonamides is presented as a class of calcitonin (CT) inducers - a potentially new method for treating diseases associated with postmenopausal bone loss such as osteoporosis. We have found that certain di-n-butylxanthine sulfonamides 4 upregulate CT transcription in a CT-luciferase reporter gene assay (CT-luci) and increase the production and release of CT in a CT secretion/RIA assay (CTS). In addition, these compounds do not have potent PDE4 inhibitory activity as do the related xanthine methylene ketones such as denbufyllene (2). One compound in particular (9) shows a transcription activation ratio (TAR) of 2.1 in CT-luci, a CTS increase of 3.6-fold, and a PDE4 (phosphodiesterase type IV) IC50 = 4.1 mu M. In addition, this compound showed a statistically significant 47% trabecular bone protection in ovariectomized-induced osteopenia (OVX) rats as determined by assay when administered for 4 weeks at 30 mg/kg/day, i.p. by quantitative computed tomography (QCT). When administered p.o., compound 9 shows 50% trabecular bone protection when administered for 3 weeks at 50 mg/kg/day, i.p. This compared with salmon CT which shows 62% trabecular bone protection when administered at 50 IU/kg/day for 4 weeks.